We are live on ! Find out more
CAM

Cormorant Asset Management Portfolio holdings

AUM $1.95B
1-Year Est. Return 773.9%
This Fund
S&P 500
This Quarter Est. Return
+52.18%
1 Year Est. Return
+773.9%
3 Year Est. Return
+3,976.92%
5 Year Est. Return
+17,750.67%
10 Year Est. Return
+592,782.78%
AUM
$649M
AUM Growth
+$162M
Cap. Flow
+$16.8M
Cap. Flow %
2.6%
Top 10 Hldgs %
48.42%
Holding
76
New
11
Increased
16
Reduced
10
Closed
6

Top Buys

Rank Stock Value
1
CELG
Celgene Corp
CELG
+$31.6M
2
ALKS icon
Alkermes
ALKS
+$17.8M
3
ARDX icon
Ardelyx
ARDX
+$15.4M
4
RGLS
Regulus Therapeutics
RGLS
+$13.3M
5
PTLA
Portola Pharmaceuticals, Inc.
PTLA
+$11.1M

Top Sells

Rank Stock Value
1
PBYI icon
Puma Biotechnology
PBYI
+$63.8M
2
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$16.1M
3
ARWR icon
Arrowhead Research
ARWR
+$13.3M
4
RCPT
RECEPTOS INC COM STK (DE)
RCPT
+$10.8M
5
AGIO icon
Agios Pharmaceuticals
AGIO
+$6.13M

Sector Composition

Rank Sector Weight
1 Healthcare 81.14%
2 Miscellaneous 18.86%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
KIN
51
DELISTED
Kindred Biosciences, Inc.
KIN
$2.61M 0.4%
350,000
– –
NGNE icon
52
Neurogene
NGNE
$694M
$2.25M 0.35%
15,000
– –
SCTL
53
DELISTED
Societal CDMO, Inc. Common Stock
SCTL
$2M 0.31%
780,500
– –
CLRB icon
54
Cellectar Biosciences
CLRB
$22.2M
$1.64M 0.25%
18
– –
AKTX
55
Akari Therapeutics
AKTX
$19.7M
$1.44M 0.22%
38
+7
+23% +$306K
BLCM
56
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
$1.38M 0.21%
+6,000
New +$1.29M
AKBA icon
57
Akebia Therapeutics
AKBA
$254M
$1.37M 0.21%
118,000
-282,000
-71% -$4.04M
AGTC
58
DELISTED
Applied Genetic Technologies Corporation
AGTC
$1.27M 0.2%
60,600
– –
GALT icon
59
Galectin Therapeutics
GALT
$371M
$1.08M 0.17%
312,000
-138,400
-31% -$612K
NERV icon
60
Minerva Neurosciences
NERV
$166M
$1.05M 0.16%
21,875
– –
SCYX icon
61
SCYNEXIS
SCYX
$40.9M
$998K 0.15%
1,250
– –
VCYT icon
62
Veracyte
VCYT
$3.1B
$968K 0.15%
+100,200
New +$782K
AGRX
63
DELISTED
Agile Therapeutics
AGRX
$921K 0.14%
75
– –
CRIS icon
64
Curis
CRIS
$2.72M
$900K 0.14%
300
– –
PTCT icon
65
PTC Therapeutics
PTCT
$5.64B
$518K 0.08%
10,000
-115,000
-92% -$5.06M
EPRS
66
DELISTED
EPIRUS BIOPHARMACEUTICALS INC COM
EPRS
$425K 0.07%
+75,000
New +$392K
NVRO
67
DELISTED
NEVRO CORP.
NVRO
$387K 0.06%
+10,000
New +$315K
SAGE
68
DELISTED
Sage Therapeutics
SAGE
$37K 0.01%
1,000
-9,000
-90% -$335K
AGIO icon
69
Agios Pharmaceuticals
AGIO
$1.97B
– –
-100,000
Closed -$6.13M
ALNY icon
70
Alnylam Pharmaceuticals
ALNY
$32B
– –
-50,000
Closed -$3.9M
ARWR icon
71
Arrowhead Research
ARWR
$9.29B
– –
-900,000
Closed -$13.3M
JAZZ icon
72
Jazz Pharmaceuticals
JAZZ
$15.8B
– –
-100,000
Closed -$16.1M
CLVS
73
DELISTED
Clovis Oncology, Inc.
CLVS
– –
-70,000
Closed -$3.17M
ZSPH
74
DELISTED
ZS PHARMA INC COMS TK (DE)
ZSPH
– –
-50,000
Closed -$1.96M
1 2
3

Similar funds

AHC
Adell Harriman & Carpenter Houston, Texas $1.95B AUM 52.72% 1-Year Est. Return
FFS
Founders Financial Securities Towson, Maryland $1.95B AUM 22.17% 1-Year Est. Return
GIP
Granite Investment Partners El Segundo, California $1.95B AUM 49.89% 1-Year Est. Return
SLF
Sun Life Financial Toronto, Ontario, Canada $1.95B AUM 25.88% 1-Year Est. Return
BFPW
BOK Financial Private Wealth Denver, Colorado $1.95B AUM 20.52% 1-Year Est. Return
MSA
MUFG Securities Americas New York $1.95B AUM 42.71% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.96B AUM 48.96% 1-Year Est. Return
GF
Greenhouse Funds Baltimore, Maryland $1.96B AUM 36.47% 1-Year Est. Return

Cormorant Asset Management's Q4 2014 Portfolio in Review

As of Q4 2014, Cormorant Asset Management held 76 positions worth $649M, up 33% from $486M the previous quarter. Its ten largest holdings account for 48% of the portfolio.

Cormorant Asset Management's Q4 2014 filing shows 11 new, 16 increased, 10 reduced and 6 closed positions. Its largest new stake was Celgene Corp: 300,000 shares worth $33.6M. The largest sale was Puma Biotechnology, an estimated $63.8M.

By sector, the portfolio is most concentrated in Healthcare at 81% of assets, down from 85% a quarter earlier, followed by Miscellaneous.

  • Cormorant Asset Management's largest Q4 2014 buy was Celgene Corp: 300,000 shares worth $33.6M.
  • Cormorant Asset Management added most to Alkermes in Q4 2014, an estimated $17.8M increase.
  • Cormorant Asset Management's biggest Q4 2014 reduction was Puma Biotechnology, cutting an estimated $63.8M.
  • Cormorant Asset Management fully exited Jazz Pharmaceuticals in Q4 2014, selling an estimated $16.1M.
  • Cormorant Asset Management's ten largest holdings make up 48% of its $649M portfolio in Q4 2014.
  • Cormorant Asset Management opened 11 new positions and closed 6 in Q4 2014.
  • Cormorant Asset Management's portfolio value rose 33% quarter-over-quarter to $649M.

Based on Cormorant Asset Management's 13F filing for Q4 2014, filed 17 Feb 2015.